Refractory human papillomavirus-associated oral warts treated topically with 1-3% cidofovir solutions in human immunodeficiency virus type 1-infected patients [18]

British Journal of Dermatology

Volumn 152, Issue 3, 2005, Pages 590-591

  Husak, R ^a   Zouboulis, C C ^a   Sander Bahr C ^a   Hummel, M ^a   Orfanos, C E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BETA INTERFERON; CIDOFOVIR; IMIQUIMOD;

ADULT; CASE REPORT; DNA SEQUENCE; DRUG FORMULATION; DRUG MECHANISM; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MOUTH DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SKIN BIOPSY; VERRUCA VULGARIS; VIRUS LOAD; WART VIRUS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOSINE; HIV-1; HUMANS; MALE; MIDDLE AGED; MOUTH DISEASES; PAPILLOMAVIRIDAE; PHOSPHONIC ACIDS; WARTS;

EID: 17444374609     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06461.x     Document Type: Letter

References (11)

1. Greenspan D, Canchola AJ, MacPhail LA et al. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001; 357:1411-12.
2. King MD, Reznik DA, O'Daniels CM et al. Human papillomavirus-associated oral warts among human immunodeficiency virus-sero-positive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002; 34:641-8.
3. Patton LL, McKaig R, Strauss R et al. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Medical Oral Pathol Oral Radiol Endod 2000; 89:299-304.
4. Lozada-Nur F, Glick M, Schubert M, Silverberg I. Use of intralesional interferon-alpha for the treatment of recalcitrant oral warts in patients with AIDS, a report of 4 cases. Oral Surg Oral Medical Oral Pathol Oral Radiol Endod 2001; 92:617-22.
5. Beutner KR, Spruance SL, Hougham AJ et al. Treatment of genital warts with an immune response modifier (imiquimod). J Am Acad Dermatol 1998; 38:230-9.
6. De Clercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology 1997; 40:295-303.
7. Andrei G, Snoeck R, Piette J et al. Antiproliferative effects of acyclic nucleoside phosphonate on human (HPV) -harbouring cell lines compared with HPV-negative cell lines. Oncol Res 1998; 10:523-3 1.
8. Hengge UR, Tietze G. Successful treatment of recalcitrant condyloma with topical cidofovir. Sex Transm Infect 2000; 76:143.
9. Martinelli C, Farese A, Mistro AD et al. Resolution of recurrent perianal condylomata acuminata by topical cidofovir in patients with HIV infection. J Eur Acad Dermatol Venereol 2001; 15:568-9.
10. Orlando G, Fasolo MM, Beretta R et al. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS 2002; 15:447-50.
11. Resnick RM, Cornelissen MTE, Wright DK et al. Detection and typing of the human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Institute 1990; 82:1477-9.